GVK Biosciences
GVK Biosciences, a leading contract research organisation headquartered in India, has established itself as a key player in the pharmaceutical and biotechnology sectors since its inception in 2001. With a strong presence in major operational regions across Asia, Europe, and North America, GVK Biosciences offers a comprehensive suite of services, including drug discovery, development, and regulatory support. The company is renowned for its innovative approach to preclinical and clinical research, leveraging advanced technologies to deliver high-quality results. GVK Biosciences has achieved significant milestones, including collaborations with global pharmaceutical companies and contributions to numerous successful drug approvals. With a commitment to excellence and a focus on client satisfaction, GVK Biosciences continues to solidify its position as a trusted partner in the life sciences industry.
DitchCarbon Score
How does GVK Biosciences's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
GVK Biosciences's score of 4 is lower than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
GVK Biosciences's reported carbon emissions
As of 2018, GVK Biosciences reported significant carbon emissions, totalling approximately 51,100,000,000 kg CO2e for Scope 1, 1,200,000,000 kg CO2e for Scope 2, and 52,300,000,000 kg CO2e for Scope 3. This indicates a substantial carbon footprint across all scopes, with Scope 1 emissions being the highest. In the preceding years, emissions data shows an upward trend, with Scope 1 emissions increasing from about 39,580,000,000 kg CO2e in 2016 to 51,890,000,000 kg CO2e in 2017, and slightly decreasing to 51,100,000,000 kg CO2e in 2018. Scope 2 emissions also peaked in 2016 at approximately 1,560,000,000 kg CO2e before declining to 1,200,000,000 kg CO2e in 2018. Scope 3 emissions rose from about 41,140,000,000 kg CO2e in 2016 to 53,320,000,000 kg CO2e in 2017, before slightly decreasing to 52,300,000,000 kg CO2e in 2018. Despite these figures, GVK Biosciences has not publicly disclosed specific reduction targets or initiatives aimed at decreasing their carbon emissions. The absence of documented reduction strategies suggests a need for enhanced climate commitments within the organisation. As the industry increasingly prioritises sustainability, GVK Biosciences may benefit from establishing clear climate goals to align with global efforts to mitigate climate change.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2016 | 2017 | 2018 | |
|---|---|---|---|
| Scope 1 | 39,580,000,000 | 00,000,000,000 | 00,000,000,000 |
| Scope 2 | 1,560,000,000 | 0,000,000,000 | 0,000,000,000 |
| Scope 3 | 41,140,000,000 | 00,000,000,000 | 00,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
GVK Biosciences is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
